Lupus Therapeutics Market to to Grow with a CAGR of 7.09% through 2030
Increasing prevalence of
Lupus and rising research and development are expected to drive the Global
Lupus Therapeutics Market in the forecast period, 2026–2030.
According to TechSci Research report, “Lupus Therapeutics Market
- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2030F”, Global Lupus
Therapeutics Market stood at USD 7.12 billion in 2024 and is anticipated to grow with a CAGR of 7.09% in the forecast period through 2030. Expanding healthcare industries and population
development, particularly in emerging economies, has raised the demand for
lupus therapeutics. Despite being a prevalent disease, lupus is often
misdiagnosed or undiagnosed, making it challenging to manage. However,
increased awareness and education of lupus have driven the global lupus
therapeutics market. Governments, healthcare organizations, and advocacy groups
have stepped up efforts to educate the public about lupus, its symptoms, and
how to manage it. These initiatives have led to more accurate diagnoses and
improved treatment options, thereby increasing demand for lupus therapeutics.
Moreover, pharmaceutical companies have also invested heavily in research and
development of lupus drugs. This has led to the introduction of new and
innovative drugs in the market, which has improved the quality of life of lupus
patients. This in turn is expected to create lucrative opportunities for the
growth of global lupus therapeutics market.
Additionally, technological advancements in
healthcare have also contributed to the growth of the lupus therapeutics
market. For instance, the use of telemedicine and wearable devices has made it
easier for doctors to monitor patients remotely, improving the management of
lupus. Furthermore, artificial intelligence and big data analytics have enabled
doctors to personalize lupus treatment, thereby improving the efficacy of the
treatment and hence accelerated the uptake of these therapeutics. Thus,
propelling the growth of the overall global lupus therapeutics market.
One of the main
challenges hampering the growth of global lupus therapeutics market is the high
cost of drugs. Many of the new drugs for lupus are expensive, making them
difficult to access for many patients. Another challenge is the complexity of
the disease itself. Lupus can manifest in various ways, making it difficult to
diagnose and treat effectively, thereby hampering the growth of global lupus
therapeutics market. Also lack of skilled healthcare professionals and limited
coverage may hamper the growth of global lupus therapeutics market.
Browse over XX market
data Figures spread through XX Pages and an in-depth TOC on "Global Lupus Therapeutics Market.”
Global Lupus Therapeutics is
segmented based on Treatment Type, Route of Administration, End-User, Regional Distribution and Company.
Based on Treatment Type, the biologics segment is poised for the most rapid growth in the forecast period. This is largely attributed to advances in the understanding of the molecular and genetic basis of lupus, which has led to the development of targeted therapies. Biologic agents such as belimumab and anifrolumab have demonstrated significant clinical efficacy in controlling disease activity in lupus patients. The increasing emphasis on precision medicine, which aims to tailor treatments to individual patient profiles, is accelerating the adoption of biologics. Moreover, the therapeutic landscape is expanding with new biologic candidates entering the development pipeline and existing drugs being approved for additional indications. These factors, along with the growing preference for treatments that offer better safety and tolerability profiles compared to traditional therapies, are expected to further bolster the biologics segment soon.
Based on the Region, the Asia-Pacific region is witnessing the fastest growth in the global lupus therapeutics market, driven by a combination of rising disease prevalence, increasing healthcare expenditure, expanding access to advanced medical treatments, and greater awareness of autoimmune disorders. Several countries in the region, including China, India, Japan, and South Korea, are seeing a steady rise in diagnosed cases of systemic lupus erythematosus (SLE), particularly among women of reproductive age, who are most susceptible to the disease. Improvements in diagnostic capabilities, along with national efforts to enhance healthcare infrastructure, are enabling earlier identification and treatment of lupus, which in turn fuels demand for effective therapeutics.
Major companies operating
in Global Lupus Therapeutics market
are:
- GSK plc.
- Novartis AG
- AstraZeneca
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- ImmuPharma PLC
- Pfizer Inc.
- Sanofi S.A.
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
Download Free Sample Report
Customers
can also request for 10% free customization on this report.
"North America was expected to dominate
the Global Lupus Therapeutics Market during the forecast period due to the
existence of significant market players, rising prevalence of lupus. Additionally,
improved healthcare infrastructure and increasing research and development by
collaborations of public and private firms are creating favorable conditions to
boost the global demand for Lupus Therapeutics till 2030. The increasing number
of clinical trials in the region especially in the United States to find a cure
for the disease is expected to support the growth of lupus therapeutics market
in the region” said Mr. Karan Chechi, Research Director of TechSci Research,
a research-based global management consulting firm.
“Lupus Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, Biologics, Others), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region & Competition, 2020-2030F", has evaluated the future growth potential of Global Lupus
Therapeutics and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Lupus Therapeutics market.”
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com